FDA Approves J and J Head and Neck Cancer Treatment
The FDA granted accelerated approval to Johnson and Johnson for an advanced head and neck cancer therapy. The treatment is for patients whose disease worsened following prior therapies.
Xurve View
Insights:
Xurve View
The United States Food and Drug Administration granted accelerated approval to JOHNSON & JOHNSON's new treatment for advanced head and neck cancer on Thursday morning. The therapy targets patients whose disease has progressed following prior chemotherapy and immunotherapy regimens. The decision expands treatment options in a difficult-to-treat oncology indication with high unmet medical need.
